Recently, Henlius successfully hosted an in-person clinical investigator meeting for the HLX22-GC-301 study in Tokyo, Japan. The meeting focused on the international phase 3 clinical trial (HLX22-GC-301) of HLX22, our innovative anti-HER2 monoclonal antibody (mAb)

Recently, the updated 3-year follow-up results of the international multicenter Phase 3 clinical trial HLX02-BC01(NCT03084237 and EudraCT: 2016-000206-10) of HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac^® in Europe), led by Academician Binghe Xu, director of the National New Drug (Antitumor) Clinical Research Center of Cancer Hospital Chinese Academy of Medical Sciences, were published in the professional breast cancer journal The Breast. The follow-up analysis results demonstrated that HANQUYOU exhibited comparable long-term efficacy, safety, and immunogenicity to the reference trastuzumab in patients with previously untreated HER2-positive metastatic breast cancer, further validating their clinical equivalence.

(26 February, 2025, Shanghai, China) — Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (“Fosun Pharma Industrial”), has received approval from the National Medical Products Administration (“NMPA”) for the New Drug Application (“NDA”) for Tenapanor Hydrochloride Tablets (Chinese trade name: Wan Ti Le, the “New Drug”), an innovative phosphate absorption inhibitor with a novel mechanism, with the indication being for the control of serum phosphorus levels in dialysis patients with chronic kidney disease (CKD) who have an inadequate response or are intolerant to phosphorus binders.

Recently, Fosun Tourism Group announced the establishment of AI Lab, focusing on the application, innovation, and implementation of artificial intelligence technology in the tourism and vacation sector. AI Lab is currently working on the development of AI G.O (AI Gentle Organizer), which will use advanced models such as DeepSeek, combined with multimodal interaction and machine learning algorithms, to provide personalized services throughout the customer journey, reconstructing every experience at Fosun Tourism Group’s destinations and resorts.

On 21 February, Guo Guangchang, Chairman of Fosun International spoke at the 25th Annual Conference of Yabuli China Entrepreneurs Forum 2025, stating that private enterprises are not afraid of competition as long as there are fair opportunities for participation. A strong commitment to product excellence will certainly lead to market opportunities.

In the wave of technological innovation, artificial intelligence (AI) has become a pivotal force driving transformation in the healthcare industry. Fosun Health, a leading medical and health technology group in China, has deeply integrated cutting-edge large model technologies and has taken the lead in adopting DeepSeek-R1, continuously exploring new frontiers in smart healthcare.

Fosun’s global operations achieved another milestone. On February 20, during the Abu Dhabi Investment Forum in Shanghai, Fosun International signed a Memorandum of Strategic Cooperation with the Abu Dhabi Investment Office (ADIO). This collaboration aims to drive the expansion of Fosun’s subsidiaries into Abu Dhabi and the broader Middle East region, injecting fresh momentum into Fosun’s global presence and industrial operations.

Recently, HANBEITAI (bevacizumab), independently developed and produced by Henlius, has been officially approved by Agencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED) for marketing in Bolivia under the trade name LONGIVA. This milestone marks HANBEITAI as the fourth self-developed and -manufactured product of Henlius to be approved for overseas marketing, following HANQUYOU (trastuzumab), HANSIZHUANG (serplulimab), and HANLIKANG (rituximab). This further propels the company's globalization process.

Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as drug research and development, medical imaging, and precision medicine through both independent research and external collaborations, thereby driving transformation and development in the pharmaceutical industry through technological advancements. At the same time, Fosun Pharma is accelerating the deeper application of AI technology in marketing, customer service, and smart office solutions, using AI to improve quality and efficiency while promoting enhanced corporate management effectiveness.